This study sought to monitor COVID-19 prevalence and course of symptoms among oncology patients in order to identify any correlations with the biological and clinical data collected from the oncology cohort.
Hospital St. Joseph sought to better understand COVID-19 incidence and course of symptoms among oncology patients. They faced an acute study design challenge: how to gather high-quality data from patients with Stage III or IV cancers undergoing chemotherapy without overburdening them.
Patients were reported to be cautious and to follow all HCP recommendations: Mask wearing, hand washing, use of sanitizer, and social distancing (excluding clinic visits). No patients were diagnosed with COVID-19 during the study.
Although 4 patients reported suspicious symptoms, all PCR tests returned negative, demonstrating the symptoms as non-COVID-19 related.
Patients reported that the Obvio-19 application was easy to use. Outcomes reporting took, on average, less than 2 minutes a day.
The ease with which the study participants interacted with the Obvio-19 app, and the success of the study design overall, is reflected in the feedback provided by several patients. These participants requested that the study duration be extended an additional 6 months, citing the daily questionnaire as a source of comfort, as well as concerns that there would be no one they could alert, if necessary, following the study’s completion.
Such participant satisfaction—in combination with high compliance and retention rates—indicate decentralized models including intuitive digital instruments might represent an effective avenue for conducting studies amongst oncology patients receiving at-home care. Study design could be adapted to meet these patients’ needs, requiring them to visit the clinics less frequently while also ensuring their compliance with tasks and medications and their safety through remote monitoring and the tracking of secondary effects.
Hospital St. Joseph sought to better understand COVID-19 incidence and course of symptoms among oncology patients. They faced an acute study design challenge: how to gather high-quality data from patients with Stage III or IV cancers undergoing chemotherapy without overburdening them.
Patients were reported to be cautious and to follow all HCP recommendations: Mask wearing, hand washing, use of sanitizer, and social distancing (excluding clinic visits). No patients were diagnosed with COVID-19 during the study.
Although 4 patients reported suspicious symptoms, all PCR tests returned negative, demonstrating the symptoms as non-COVID-19 related.
Patients reported that the Obvio-19 application was easy to use. Outcomes reporting took, on average, less than 2 minutes a day.
The ease with which the study participants interacted with the Obvio-19 app, and the success of the study design overall, is reflected in the feedback provided by several patients. These participants requested that the study duration be extended an additional 6 months, citing the daily questionnaire as a source of comfort, as well as concerns that there would be no one they could alert, if necessary, following the study’s completion.
Such participant satisfaction—in combination with high compliance and retention rates—indicate decentralized models including intuitive digital instruments might represent an effective avenue for conducting studies amongst oncology patients receiving at-home care. Study design could be adapted to meet these patients’ needs, requiring them to visit the clinics less frequently while also ensuring their compliance with tasks and medications and their safety through remote monitoring and the tracking of secondary effects.
This study sought to monitor COVID-19 prevalence and course of symptoms among oncology patients in order to identify any correlations with the biological and clinical data collected from the oncology cohort.
Hospital St. Joseph sought to better understand COVID-19 incidence and course of symptoms among oncology patients. They faced an acute study design challenge: how to gather high-quality data from patients with Stage III or IV cancers undergoing chemotherapy without overburdening them.
Patients were reported to be cautious and to follow all HCP recommendations: Mask wearing, hand washing, use of sanitizer, and social distancing (excluding clinic visits). No patients were diagnosed with COVID-19 during the study.
Although 4 patients reported suspicious symptoms, all PCR tests returned negative, demonstrating the symptoms as non-COVID-19 related.
Patients reported that the Obvio-19 application was easy to use. Outcomes reporting took, on average, less than 2 minutes a day.
The ease with which the study participants interacted with the Obvio-19 app, and the success of the study design overall, is reflected in the feedback provided by several patients. These participants requested that the study duration be extended an additional 6 months, citing the daily questionnaire as a source of comfort, as well as concerns that there would be no one they could alert, if necessary, following the study’s completion.
Such participant satisfaction—in combination with high compliance and retention rates—indicate decentralized models including intuitive digital instruments might represent an effective avenue for conducting studies amongst oncology patients receiving at-home care. Study design could be adapted to meet these patients’ needs, requiring them to visit the clinics less frequently while also ensuring their compliance with tasks and medications and their safety through remote monitoring and the tracking of secondary effects.
Hospital St. Joseph sought to better understand COVID-19 incidence and course of symptoms among oncology patients. They faced an acute study design challenge: how to gather high-quality data from patients with Stage III or IV cancers undergoing chemotherapy without overburdening them.
Patients were reported to be cautious and to follow all HCP recommendations: Mask wearing, hand washing, use of sanitizer, and social distancing (excluding clinic visits). No patients were diagnosed with COVID-19 during the study.
Although 4 patients reported suspicious symptoms, all PCR tests returned negative, demonstrating the symptoms as non-COVID-19 related.
Patients reported that the Obvio-19 application was easy to use. Outcomes reporting took, on average, less than 2 minutes a day.
The ease with which the study participants interacted with the Obvio-19 app, and the success of the study design overall, is reflected in the feedback provided by several patients. These participants requested that the study duration be extended an additional 6 months, citing the daily questionnaire as a source of comfort, as well as concerns that there would be no one they could alert, if necessary, following the study’s completion.
Such participant satisfaction—in combination with high compliance and retention rates—indicate decentralized models including intuitive digital instruments might represent an effective avenue for conducting studies amongst oncology patients receiving at-home care. Study design could be adapted to meet these patients’ needs, requiring them to visit the clinics less frequently while also ensuring their compliance with tasks and medications and their safety through remote monitoring and the tracking of secondary effects.
Hospital St. Joseph sought to better understand COVID-19 incidence and course of symptoms among oncology patients. They faced an acute study design challenge: how to gather high-quality data from patients with Stage III or IV cancers undergoing chemotherapy without overburdening them.
Patients were reported to be cautious and to follow all HCP recommendations: Mask wearing, hand washing, use of sanitizer, and social distancing (excluding clinic visits). No patients were diagnosed with COVID-19 during the study.
Although 4 patients reported suspicious symptoms, all PCR tests returned negative, demonstrating the symptoms as non-COVID-19 related.
Patients reported that the Obvio-19 application was easy to use. Outcomes reporting took, on average, less than 2 minutes a day.
The ease with which the study participants interacted with the Obvio-19 app, and the success of the study design overall, is reflected in the feedback provided by several patients. These participants requested that the study duration be extended an additional 6 months, citing the daily questionnaire as a source of comfort, as well as concerns that there would be no one they could alert, if necessary, following the study’s completion.
Such participant satisfaction—in combination with high compliance and retention rates—indicate decentralized models including intuitive digital instruments might represent an effective avenue for conducting studies amongst oncology patients receiving at-home care. Study design could be adapted to meet these patients’ needs, requiring them to visit the clinics less frequently while also ensuring their compliance with tasks and medications and their safety through remote monitoring and the tracking of secondary effects.
This study sought to monitor COVID-19 prevalence and course of symptoms among oncology patients in order to identify any correlations with the biological and clinical data collected from the oncology cohort.
Hospital St. Joseph sought to better understand COVID-19 incidence and course of symptoms among oncology patients. They faced an acute study design challenge: how to gather high-quality data from patients with Stage III or IV cancers undergoing chemotherapy without overburdening them.
Patients were reported to be cautious and to follow all HCP recommendations: Mask wearing, hand washing, use of sanitizer, and social distancing (excluding clinic visits). No patients were diagnosed with COVID-19 during the study.
Although 4 patients reported suspicious symptoms, all PCR tests returned negative, demonstrating the symptoms as non-COVID-19 related.
Patients reported that the Obvio-19 application was easy to use. Outcomes reporting took, on average, less than 2 minutes a day.
The ease with which the study participants interacted with the Obvio-19 app, and the success of the study design overall, is reflected in the feedback provided by several patients. These participants requested that the study duration be extended an additional 6 months, citing the daily questionnaire as a source of comfort, as well as concerns that there would be no one they could alert, if necessary, following the study’s completion.
Such participant satisfaction—in combination with high compliance and retention rates—indicate decentralized models including intuitive digital instruments might represent an effective avenue for conducting studies amongst oncology patients receiving at-home care. Study design could be adapted to meet these patients’ needs, requiring them to visit the clinics less frequently while also ensuring their compliance with tasks and medications and their safety through remote monitoring and the tracking of secondary effects.
This study sought to monitor COVID-19 prevalence and course of symptoms among oncology patients in order to identify any correlations with the biological and clinical data collected from the oncology cohort.
Hospital St. Joseph sought to better understand COVID-19 incidence and course of symptoms among oncology patients. They faced an acute study design challenge: how to gather high-quality data from patients with Stage III or IV cancers undergoing chemotherapy without overburdening them.
Patients were reported to be cautious and to follow all HCP recommendations: Mask wearing, hand washing, use of sanitizer, and social distancing (excluding clinic visits). No patients were diagnosed with COVID-19 during the study.
Although 4 patients reported suspicious symptoms, all PCR tests returned negative, demonstrating the symptoms as non-COVID-19 related.
Patients reported that the Obvio-19 application was easy to use. Outcomes reporting took, on average, less than 2 minutes a day.
The ease with which the study participants interacted with the Obvio-19 app, and the success of the study design overall, is reflected in the feedback provided by several patients. These participants requested that the study duration be extended an additional 6 months, citing the daily questionnaire as a source of comfort, as well as concerns that there would be no one they could alert, if necessary, following the study’s completion.
Such participant satisfaction—in combination with high compliance and retention rates—indicate decentralized models including intuitive digital instruments might represent an effective avenue for conducting studies amongst oncology patients receiving at-home care. Study design could be adapted to meet these patients’ needs, requiring them to visit the clinics less frequently while also ensuring their compliance with tasks and medications and their safety through remote monitoring and the tracking of secondary effects.
VaxArt needed solutions for evaluating the safety and immunogenicity of its orally administered norovirus vaccine. Of particular importance was incorporating a way to quickly detect severe reactogenicity symptoms during the first week following vaccine administration.
A global pharmaceutical company needed to understand the impact of a dissociative anesthetic on quality of life in patients with treatment-resistant depression. The company sought a way to gather high-quality data and carefully monitor suicidality.